Research programme: capsid protein VP1 therapeutics - Gene Vector TechnologiesAlternative Names: BL-4040
Latest Information Update: 07 Jul 2011
At a glance
- Originator Gene Vector Technologies
- Developer BioLineRx
- Mechanism of Action Apoptosis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Acute kidney injury
Most Recent Events
- 07 Jul 2011 Preclinical development for Acute kidney injury is ongoing in Israel
- 27 Aug 2007 Preclinical trials in Acute kidney injury in Israel (unspecified route)
- 27 Aug 2007 BL 4040 licensed to Gene Vector Technologies worldwide